NeuroTherapia, Inc., a Cleveland Clinic spin-off company, was founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, and the Cleveland Clinic. NeuroTherapia is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of the lead compound, NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer’s disease. NeuroTherapia is currently performing preclinical safety studies and plans on studying NTRX-07 in humans in late 2016, early 2017.